Anticoagulation with citrate-containing haemodialysate (cHD) is an alternative to tinzaparin haemodialysate (tHD). The study investigated whether cHD would differ when changed from tHD. The same 18 patients were their own controls followed up with cHD for 5 months. LDL-cholesterol decreased at the end of a cHD session (p = 0.01). Neutrophils (p = 0.013) and monocytes (p = 0.007) dropped more during a cHD session. During the follow-up period of cHD, approximately 50% needed additional tinzaparin. Before the cHD session could start, there was a lower total cholesterol at 2 weeks (p = 0.014) and LDL-cholesterol at 1 month (p = 0.011) versus an increase of LDL at 5 months (p = 0.02). Only patients without additional tinzaparin had a reduction of -C-reactive protein (CRP) at 2 months of cHD (p < 0.05) but not later. Solely cHD seems possible only in half of the patients. A greater reduction in granulocytes and monocytes during cHD indicates a more extensive blood membrane interaction, while CRP may be lower.

Keywords:
Biocompatibility, Blood purification, Citrate, Haemodialysis, Haemoglobin, Heparin
1.
Bartels PC, Schoorl M, Schoorl M, Wiering JG, Nube MJ: Activation of coagulation during treatment with haemodialysis. Scand J Clin Lab Invest 2000; 60: 283–290.
2.
Breiterman-White R: Sodium citrate use for anticoagulation in hemodialysis. ANNA J 1995; 22: 607–609.
3.
Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G: Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis 2005; 45: 557–564.
4.
Ahmad S, Callan R, Cole JJ, Blagg CR: Dialysate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis 2000; 35: 493–499.
5.
Gabutti L, Lucchini B, Marone C, Alberio L, Burnier M: Citrate- vs. Acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base status, and electrolytes. BMC Nephrol 2009; 10: 7.
6.
Ahmad S, Callan R, Cole J, Blagg C: Increased dialyzer reuse with citrate dialysate. Hemodial Int 2005; 9: 264–267.
7.
Gritters M, Borgdorff P, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Tangelder GJ, Nube MJ: Reduction in platelet activation by citrate anticoagulation does not prevent intradialytic hemodynamic instability. Nephron Clin Pract 2007; 106:c9–c16.
8.
Kossmann RJ, Gonzales A, Callan R, Ahmad S: Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol 2009; 4: 1459–1464.
9.
Chevreuil O, Hultin M, Ostergaard P, Olivecrona T: Depletion of lipoprotein lipase after heparin administration. Arterioscler Thromb 1993; 13: 1391–1396.
10.
Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG: Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. J Lab Clin Med 2001; 138: 206–213.
11.
Nasstrom B, Stegmayr B, Olivecrona G, Olivecrona T: Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. BMC Nephrol 2004; 5: 17.
12.
Nasstrom B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T: A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant 2005; 20: 1172–1179.
13.
Mahmood D, Grubbstrom M, Lundberg LD, Olivecrona G, Olivecrona T, Stegmayr BG: Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis. BMC Nephrol 2010; 11: 33.
14.
Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A, Carter M, Sergeyeva O, Korth L, Maunsell E, Zhu Y, Krishnan M, Diaz-Buxo JA: Effects of citrate acid concentrate (citrasate®) on heparin n requirements and hemodialysis adequacy: A multicenter, prospective noninferiority trial. Blood Purif 2012; 33: 199–204.
15.
Stegmayr BG, Jonsson P, Mahmood D: A significant proportion of patients treated with citrate containing dialysate need additional anticoagulation. Int J Artif Organs 2013; 36: 1–6.
16.
Mahmood D, Makoveichuk E, Nilsson S, Olivecrona G, Stegmayr B: Response of angiopoietin-like proteins 3 and 4 to hemodialysis. Int J Artif Organs 2014; 37: 13–20.
17.
Masuda A, Hagiwara S, Tanimoto M, Kodama F, Okumura K, Nohara N, Matsumoto M, Maiguma M, Omote K, Io H, Kurusu A, Ohsawa I, Shimizu Y, Hamada C, Horikoshi S, Tomino Y: Effects of acetate-free citrate dialysate on glycoxidation and lipid peroxidation products in hemodialysis patients. Nephron Extra 2012; 2: 256–268.
18.
Parkin J, Cohen B: An overview of the immune system. Lancet 2001; 357: 1777–1789.
19.
Yamashiro S, Kamohara H, Wang JM, Yang D, Gong WH, Yoshimura T: Phenotypic and functional change of cytokine-activated neutrophils: Inflammatory neutrophils are heterogeneous and enhance adaptive immune responses. J Leukoc Biol 2001; 69: 698–704.
20.
Dale DC, Boxer L, Liles WC: The phagocytes: neutrophils and monocytes. Blood 2008; 112: 935–945.
21.
Furie MB, McHugh DD: Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-alpha. J Immunol 1989; 143: 3309–3317.
22.
Skagerlind MSE, Stegmayr BG: An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis. Eur J Clin Pharmacol 2018; 74: 267–274.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.